2.2. Pediatrics
Although treatment durations have not been solidified, experts recommend that dalteparin therapy should be continued for less than or equal to 3 months in pediatric patients with provoked DVT or PE and up to 12 months (range, 6 to 12 months) in pediatric patients with unprovoked DVT or PE15. Dalteparin treatment recommendations for pediatric patients are summarized in Table 4.
Treatment Indication | Drug Name | Treatment Duration Range | Maximum Treatment Duration |
---|---|---|---|
Venous thromboembolism treatment | Dalteparin | 3 to 12 months | 12 months |